Imilastin indications
Intravenous
Susceptible infections
Adult: Combined with Imilastin: (as anhydrous Imilastin) 1-2 g daily in divided doses every 6-8 hr, given via IV infusion. Doses 250 or 500 mg are infused over 20-30 min, and doses of 750 mg or 1 g over 40-60 min. Max: 4 g/day or 50 mg/kg.
Child: >40 kg: same as adult dose. Child >3 mth and <40 kg: 15-25 mg/kg every 6 hr by IV infusion. Doses up to 90 mg/kg may be given to older children with cystic fibrosis. Neonates and infants <3 mth: 4 wk-3 mth, 25 mg/kg every 6 hr; 1-4 wk, 25 mg/kg every 8 hr; up to 1 wk, 25 mg/kg every 12 hr. Max: >40 kg: 4 g/day or 50 mg/kg; <40 kg: 2 g/day.
Renal impairment: Max doses based on CrCl.
| CrCl (ml/min) | Dosage Recommendation |
| 31-70 | 500 mg every 6-8 hr. |
| 21-30 | 500 mg every 8-12 hr. |
| 6-20 | 250 mg or 3.5 mg/kg (whichever is lower) every 12 hr. |
| ≤5 | Only give if haemodialysis is started within 48 hr. |
Intravenous
Prophylaxis of surgical infections
Adult: 1 g may be given on induction of anaesthesia, followed by 1 g 3 hr later, with additional doses of 500 mg at 8 and 16 hr after induction if necessary.
Intramuscular
Mild to moderate susceptible infections
Adult: 500 or 750 mg every 12 hr.
Intramuscular
Uncomplicated gonorrhoea
Adult: 500 mg as a single dose.
Uses of Imilastin in details
Imilastin in combination with Imilastin (inhibitor of enzyme dehydropeptidase) is used to treat bacterial infections of lung (pneumonia), urinary tract, abdomen, blood, skin and soft tissue. It is also used to treat infections during or after delivery. It may be used in the management of fever of patients with reduced immunity due to low white blood cells (neutropenia).
Imilastin description
Semisynthetic thienamycin that has a wide spectrum of antibacterial activity against gram-negative and gram-positive aerobic and anaerobic bacteria, including many multiresistant strains. It is stable to beta-lactamases. Clinical studies have demonstrated high efficacy in the treatment of infections of various body systems. Its effectiveness is enhanced when it is administered in combination with Imilastin, a renal dipeptidase inhibitor. [PubChem]
Imilastin dosage
Intravenous
Susceptible infections
Adult: Combined with Imilastin: (as anhydrous Imilastin) 1-2 g daily in divided doses every 6-8 hr, given via IV infusion. Doses 250 or 500 mg are infused over 20-30 min, and doses of 750 mg or 1 g over 40-60 min. Max: 4 g/day or 50 mg/kg.
Child: >40 kg: same as adult dose. Child >3 mth and <40 kg: 15-25 mg/kg every 6 hr by IV infusion. Doses up to 90 mg/kg may be given to older children with cystic fibrosis. Neonates and infants <3 mth: 4 wk-3 mth, 25 mg/kg every 6 hr; 1-4 wk, 25 mg/kg every 8 hr; up to 1 wk, 25 mg/kg every 12 hr. Max: >40 kg: 4 g/day or 50 mg/kg; <40 kg: 2 g/day.
Renal impairment: Max doses based on CrCl.
| CrCl (ml/min) | Dosage Recommendation |
| 31-70 | 500 mg every 6-8 hr. |
| 21-30 | 500 mg every 8-12 hr. |
| 6-20 | 250 mg or 3.5 mg/kg (whichever is lower) every 12 hr. |
| ≤5 | Only give if haemodialysis is started within 48 hr. |
Intravenous
Prophylaxis of surgical infections
Adult: 1 g may be given on induction of anaesthesia, followed by 1 g 3 hr later, with additional doses of 500 mg at 8 and 16 hr after induction if necessary.
Intramuscular
Mild to moderate susceptible infections
Adult: 500 or 750 mg every 12 hr.
Intramuscular
Uncomplicated gonorrhoea
Adult: 500 mg as a single dose.
Imilastin interactions
Increased risk of seizures when used with ganciclovir. Ciclosporin may increase neurotoxicity of ifosfamide; ifosfamide may also raise serum levels of ciclosporin. Serum levels may be increased by uricosuric agents. May reduce efficacy of valproic acid; monitor.
Imilastin side effects
Skin rashes, urticaria, eosinophilia, fever, nausea, vomiting, diarrhoea, tooth or tongue discoloration, and altered taste. Erythema multiforme, exfoliative dermatitis. Pain and thrombophlebitis may occur at the inj site.
Potentially Fatal: Severe anaphylactic reactions. Stevens-Johnson syndrome and toxic epidermal necrolysis.
Imilastin contraindications
Hypersensitivity.
Active ingredient matches for Imilastin:
| Unit description / dosage (Manufacturer) | Price, USD |
| Imilastin 500+500 Injection | $ 0.01 |
| IMILASTIN 500MG/500MG INJECTION 1 vial / 1 injection each (Samarth Life Sciences Pvt Ltd) | $ 6.78 |
| Imilastin 500 mg/500 mg Injection (Samarth Life Sciences Pvt Ltd) | $ 6.78 |
List of Imilastin substitutes (brand and generic names): | |
| CILANE MONO | |
| CILANE MONO 500MG INJECTION 1 vial / 1 injection each (Ranbaxy Laboratories Ltd) | $ 15.31 |
| Cilapen (Taiwan) | |
| Cilapen 250 mg x 1's (Olcare) | |
| Cilapen 500 mg x 1's (Olcare) | |
| Cilapen Cilastatin 500 mg, imipenem500 mg INJ / 1 (Olcare) | $ 15.06 |
| Cilastatin (Algeria, Belgium, Bosnia & Herzegowina, Bulgaria, Chile, China, Colombia, Costa Rica, Croatia (Hrvatska), Czech Republic, Ecuador, El Salvador, Estonia, Finland, France, Guatemala, Honduras, Hong Kong, Iceland, Indonesia, Israel, Italy, Japan, Latvia, Lithuania, Luxembourg, Malaysia, Netherlands, Nicaragua, Norway, Oman, Panama, Peru, Philippines, Poland, Portugal, Romania, Russian Federation, Serbia, Singapore, Slovakia, South Africa, Spain, Sri Lanka, Sweden, Switzerland, Taiwan, Thailand, Tunisia, Turkey) | |
| Cilaxter 500 Injection | |
| Cilaxter 500 Injection (Alkem Laboratories Ltd) | $ 0.01 |
| I Nem Inj | |
| I Nem Inj 500+500 Injection (Glenmark Pharmaceuticals Ltd.) | $ 0.01 |
| IC2 | |
| IC2 250MG INJECTION 1 vial / 1 injection each (Unimark Remedies Ltd) | $ 11.30 |
| IC2 500MG INJECTION 1 vial / 1 injection each (Unimark Remedies Ltd) | $ 15.60 |
| IC2 500mg Injection (Unimark Remedies Ltd) | $ 15.60 |
| IMC | |
| IMC 250+250 Injection (Uniword Marketing (P) Ltd) | $ 0.01 |
| IMCI | |
| IMCI 500MG INJECTION 1 vial / 1 ML injection each (Parenteral Drugs India Ltd) | $ 12.51 |
| Ime Cila | |
| Ime Cila 250+250 Injection (Abbott Healthcare Pvt Ltd (AHPL)) | $ 8.46 |
| Ime Cila 500+500 Injection (Abbott Healthcare Pvt Ltd (AHPL)) | $ 0.01 |
| IME CILA 500MG/500MG INJECTION 1 vial / 1 injection each (Abbott Healthcare Pvt Ltd (AHPL)) | $ 19.46 |
| Imipecil (Argentina) | |
| Imipenem (Algeria, Belgium, Bosnia & Herzegowina, Bulgaria, Chile, China, Colombia, Costa Rica, Croatia (Hrvatska), Czech Republic, Ecuador, El Salvador, Estonia, Finland, France, Georgia, Guatemala, Honduras, Hong Kong, Iceland, Indonesia, Israel, Italy, Japan, Latvia, Lithuania, Luxembourg, Malaysia, Netherlands, Nicaragua, Norway, Oman, Panama, Peru, Philippines, Poland, Portugal, Romania, Russian Federation, Serbia, Singapore, Slovakia, South Africa, Spain, Sri Lanka, Sweden, Switzerland, Taiwan, Thailand, Tunisia, Turkey) | |
| Imipénem | |
| Imipenem + Cilastatina (Argentina) | |
| Imipenem + Cilastatina Venus Pharma (Colombia, Portugal) | |
| Imipenem Drawer (Argentina) | |
| Implatin | |
| Implatin 250+250 Injection (Mickle Pharma) | $ 8.13 |
| Opostibac (Mexico) | |
| Sanam | |
| Sanam 250+250 Injection (Stellar Life Sciences) | $ 0.01 |
| Tienamycin | |
| Tiesilan (Colombia) | |
| VE IC | |
| VE IC 500+500 Injection (Biovista Lifesciences) | $ 0.01 |
| VE IC 250+250 Injection (Biovista Lifesciences) | $ 8.07 |
| Vocef | |
| Vocef 250+250 Injection (Vokin Biotech Pvt. Ltd.) | $ 0.01 |
| Vocef 500+500 Injection (Vokin Biotech Pvt. Ltd.) | $ 0.02 |
References
- DailyMed. "CILASTATIN SODIUM; IMIPENEM: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- DailyMed. "CILASTATIN SODIUM: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- PubChem. "Cilastatin". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Imilastin are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Imilastin. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported useful
No survey data has been collected yetConsumer reported price estimates
No survey data has been collected yetConsumer reported time for results
No survey data has been collected yetConsumer reported age
No survey data has been collected yetConsumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
